Are peptides legal?

The short version

Are peptides legal? Some are, some are not, and the word "peptide" will not tell you which.

• An FDA-approved peptide medicine is legal with a prescription from a licensed clinician.
• A compounded peptide, one a licensed pharmacy makes to order for you, can be legal. The prescription has to be real, and the pharmacy has to meet the federal and state compounding rules.
• A vial sold online as "research use only" does not count as a legal route to care. The FDA has told sellers of these products that they are breaking federal law.

This page explains the rules. It is not legal advice.

"Peptide" is not a legal category

No U.S. law sorts products into "peptides" and "not peptides". What the law cares about is whether something is a drug.

Under federal law, something counts as a drug when it is intended to diagnose, treat, relieve or prevent disease, or to alter the body's structure or the way it works. "Meant to" is judged by what the seller says and does, not only by the words on the label. That is why the same peptide can sit under two sets of rules. In a face cream sold to improve how skin looks, it can be a cosmetic, which needs no FDA approval. Sold for injection, it is judged as a drug.

Three routes, three sets of rules

Approved medicines

A drug company shows the Food and Drug Administration (FDA), the U.S. agency that reviews medicines, that its product works and is acceptably safe for a specific use. Semaglutide and tirzepatide are both the active ingredients in approved medicines.

Compounded medicines

Compounding means a pharmacy makes a medicine to order instead of handing over a factory-made product. The law allows two kinds of compounder:

• A 503A pharmacy, named after a section of the law, is an ordinary state-licensed pharmacy preparing a medicine for an individual patient with a prescription.
• A 503B outsourcing facility makes larger batches of sterile medicines and follows the same manufacturing rules as drug factories.

For an ordinary 503A pharmacy, the raw ingredient must meet an official quality standard if one exists; if none exists, be part of an FDA-approved drug; failing both, be on a short federal list. The FDA adds to that list only through formal rule-making.

Compounded medicines are real medicines, but they are not FDA-approved. Nobody at the FDA confirms, before they reach you, that they work, that they are safe, or that they were made properly.

Research-use-only products

These are vials sold online as "for research use only" or "not for human consumption". Federal law generally requires FDA approval for a new drug sold across state lines; qualifying compounded medicines have separate exemptions. In warning letters in 2026, the FDA told peptide sellers that their research-only labels did not change the facts. Their own websites showed the products were meant for people, so the FDA treated them as unapproved new drugs. Selling mixing water and dosing calculators beside the vials helped show that.

Why the answer changes from one peptide to the next

Semaglutide and tirzepatide. Approved versions exist. For a time they were in national short supply, and during a shortage the law lets pharmacies make copies. The FDA declared the tirzepatide shortage over on December 19, 2024, and the semaglutide shortage over on February 21, 2025. Since the shortages ended, federal law limits when a pharmacy may compound what the law calls "essentially a copy" of an approved drug, and a lower price is not a reason the FDA accepts. Compounded versions are not FDA-approved, and FDA-approved versions exist.

BPC-157, TB-500 and similar peptides. None has ever been approved in the U.S. The FDA had put them in "Category 2", its group of ingredients that may present significant safety risks. On FDA's page current as of April 22, 2026, BPC-157, TB-500, injectable GHK-Cu and more than a dozen others appear in a separate table of requests that were "nominated but withdrawn", not in Category 2. That is not approval. The organisations that had nominated them withdrew their nominations, and the FDA still prints its safety concerns beside each one.

In July 2026, an FDA advisory committee met to discuss seven of these peptides, including BPC-157 and TB-500. Before the meeting, FDA staff proposed against listing each of them. As of September 2026, the FDA had published no record of how the committee voted. Even a yes vote would be advice only: changing the list takes a formal rule-making process with public comment.

GHK-Cu. In skin creams, GHK-Cu is a cosmetic ingredient. For injection, it sits in the withdrawn table above. For forms that are not injected, the FDA's list updated May 14, 2026 puts it in Category 1, meaning the FDA has said it will hold off on enforcement against pharmacies that follow its conditions while it decides. That is a policy of holding off, not an approval.

Sermorelin. Sermorelin was once an approved medicine. The FDA withdrew that approval in 2009, and no approved version is sold today, so any sermorelin prescribed now is a compounded preparation.

What is lawful to buy, and what is not

Generally lawful:

• An approved medicine, prescribed for you by a licensed clinician and filled at a state-licensed pharmacy.
• A compounded medicine, prescribed for you and prepared by a licensed pharmacy that meets the federal and state compounding rules. Most states also expect a pharmacy based elsewhere to be licensed by your own state before it ships to you.
• A cosmetic cream sold for how skin looks. That is a separate set of rules from medicines.

Not lawful:

• A prescription medicine sold without a prescription. Federal law allows these medicines to be dispensed only on a licensed prescriber's order.
• A "research use only" peptide sold for people to use. The FDA has told sellers this breaks federal law, and it is not a lawful route to treatment.
• In most cases, ordering a medicine from another country for your own use. The FDA says this is usually illegal, especially when the drug is not approved in the U.S.

Rules also change from state to state

Each state writes its own rules for online prescribing. The clinician has to be licensed in the state where you are when you are seen. Some states, such as Idaho, do not accept a prescription based solely on a static online questionnaire. Others, such as California, allow a questionnaire if the care meets the proper standard.

For the safety side of the same question, read are peptides safe?

A prescription route

Promise Peptides is a U.S. telehealth platform. Promise prescribes peptides now through licensed U.S. providers. A licensed U.S. provider reviews every request and your health history, then decides whether to prescribe. Not everyone qualifies, and the answer can be no. Prescribed medicines are prepared by licensed U.S. compounding pharmacies. Each pharmacy separately decides whether it can lawfully prepare a prescription; a prescription does not guarantee it will be filled. Compounded medicines are not FDA-approved. U.S. patients only. Availability varies by state and by treatment. Promise is LegitScript-certified. That certification is not FDA approval.

Visit Promise Peptides for energy

Neo may earn money when readers become Promise patients.

Sources

1. 21 U.S.C. 321, Definitions (the legal meaning of "drug")Office of the Law Revision Counsel, U.S. House of Representatives
2. 21 CFR 201.128, Meaning of "intended uses"eCFR, National Archives
3. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)U.S. Food and Drug Administration
4. Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration
5. 21 U.S.C. 353a, Pharmacy compounding (section 503A)Legal Information Institute, Cornell Law School
6. 21 U.S.C. 353b, Outsourcing facilities (section 503B)Legal Information Institute, Cornell Law School
7. 21 CFR 216.23, Bulk drug substances that can be used to compound under section 503ALegal Information Institute, Cornell Law School
8. 21 U.S.C. 355, New drugsOffice of the Law Revision Counsel, U.S. House of Representatives
9. Warning Letters (searchable database)U.S. Food and Drug Administration
10. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilizeU.S. Food and Drug Administration
11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration
12. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category 1, 2 and 3 lists)U.S. Food and Drug Administration
13. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration
14. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration
15. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: IntroductionU.S. Food and Drug Administration
16. Drugs@FDA: FDA-Approved DrugsU.S. Food and Drug Administration
17. 21 U.S.C. 353, Exemptions and consideration for certain drugs (prescription requirement)Office of the Law Revision Counsel, U.S. House of Representatives
18. Pharmacy Permits (out-of-state pharmacies)North Carolina Board of Pharmacy
19. Personal ImportationU.S. Food and Drug Administration
20. The Appropriate Use of Telemedicine Technologies in the Practice of MedicineFederation of State Medical Boards
21. Idaho Code 54-1733, Prescription drug ordersIdaho State Legislature
22. Cal. Bus. & Prof. Code 2242California Legislative Information, State of California